Loading
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Previous close
$7.16
+$0.19 · +2.73%
After-hours
$6.91
−$0.25 · -3.49%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Day range
Current $7.16
52-week range
Current $7.16
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
34
Expensive
Sentiment
58
Mixed
Risk
39
Moderate Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Day range
Current $7.16
52-week range
Current $7.16
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 24.05M USD | — | — | — |
| Cost of goods sold | 3.5M USD | 3.15M USD | — | 250K USD |
| Gross profit | 20.55M USD | −3.15M USD | — | −250K USD |
| Research and development | 386M USD | 265.55M USD | 137.68M USD | 101.05M USD |
| Selling, general, and administrative | 91.86M USD | 35.2M USD | 20.5M USD | 12.55M USD |
| Operating expenses | 447.76M USD | 297.6M USD | 158.17M USD | 113.6M USD |
| Interest income | 14.18M USD | 12.02M USD | 3.37M USD | 1.99M USD |
| Depreciation and amortization | 3.5M USD | 3.15M USD | 1.28M USD | 250K USD |
| Operating income | −427.2M USD | −300.75M USD | −158.17M USD | −113.85M USD |
| Net income | −243.33M USD | −294.23M USD | −154.99M USD | −111.93M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$29.57
312.99% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
